Best Multiple Myeloma Patients Podcasts (2025)

1
For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress 1:30:22

Play Pause

2h ago1:30:22

1:30:22

Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas 20:08

4d ago20:08

20:08

In this week's episode, we'll learn about rapid, high-sensitivity diagnostic assays for TTP, or thrombotic thrombocytopenic purpura, that can reduce unnecessary treatments. After that: enhancing PD-1 blockade in relapsed/refractory extranodal NK/T-cell lymphoma. In a single-arm, phase 2 study, combined CD38 and PD-1 inhibition demonstrated durable …

1
Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:59:42

4d ago1:59:42

1:59:42

Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehe…

1
For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress 1:26:53

9d ago1:26:53

1:26:53

Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here.By Dr. Neil Love

1
A novel mouse model of sickle cell SC disease; multiple myeloma induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone; and splicing factor mutations in myelodysplastic syndromes ... 19:08

11d ago19:08

19:08

In this week's episode we’ll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicin…

1
014 Stem cells : what they are, mobilisation and collection. 27:41

12d ago27:41

27:41

Welcome to The Myeloma Minutes. We've now moved to a fortnightly release schedule, so you can now hear us every-other Thursday. During this episode, Jam & Sally give an in-depth, patient-friendly guide to stem cell mobilisation - the essential step before undergoing an autologous stem cell transplant for multiple myeloma. 📌Key Takeaways: Stem cells…

1
For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress 1:26:22

16d ago1:26:22

1:26:22

Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here.By Dr. Neil Love

1
An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MM 18:24

18d ago18:24

18:24

In this week's episode, we'll learn about using AI to assess transplant risk in myelofibrosis. In a step toward personalized medicine, researchers report on a machine learning model that identifies 25% of patients with poor outcomes. After that: preventing priapism in men with sickle cell anemia. A recent phase 2 feasibility study shows high rates …

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

19d ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…

1
Children as Caregivers for a Loved One with Cancer 56:06

20d ago56:06

56:06

- Definition of a Caregiver- What Research Tells Us About Children as Caregivers’ Well Being- Children as Caregivers- Children as Caregivers for a Sibling- Children as Caregivers for a Parent- Children as Caregivers for a Grandparent- Children as Caregivers for an Older Adult- Children as Caregivers for a Younger Adult- Children as Caregivers for C…

1
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies 54:07

21d ago54:07

54:07

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.By Dr. Neil Love

1
Ep 205 Leading from the Inside Out: Building Teams, Trust and Purpose in Emergency Medicine 1:38:05

20d ago1:38:05

1:38:05

In this podcast, with Dr. Thom Mayer, Dr. Carolyn Snider and Dr. Howard Ovens, on leading from the inside out, we cover foundational principles, practical habits, and transformative insights that can make any member of an ED team a more effective, compassionate, and adaptive leader. Here, you’ll find tools, philosophy, and stories that just might t…

1
Pomalidomide: A Step on the PATH Forward for Treatment of Hereditary Hemorrhagic Telangiectasia 22:00

21d ago22:00

22:00

In this episode, Contributing Editor Surbhi Shah, MBBS, MD, a clinician, researcher, and educator at Mayo Clinic in Phoenix, Arizona, talks with Keith McCrae, MD, director of classical hematology at the Taussig Cancer Institute and professor of molecular medicine at the Cleveland Clinic Lerner College of Medicine in Ohio. They discuss a recent pape…

1
Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and ... 19:38

21d ago19:38

19:38

In this week's episode, we’ll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identifi…

1
013 Trojan Horse Therapy for Myeloma: A First for the NHS 32:11

25d ago32:11

32:11

Welcome to The Myeloma Minutes. During this episode, Jam & Sally talk about a ground-breaking new combination therapy for multiple myeloma available on the NHS from this week. They highlight how it works, who it’s for, and what patients need to know. 📌Key Takeaways: A new 'Trojan horse' drug is now approved on the NHS for first relapse myeloma. Tre…

1
Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets 41:28

25d ago41:28

41:28

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma. See the full review series on high risk lymphoma…

1
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances 59:09

26d ago59:09

59:09

Prof Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to dise…

1
Diverse Populations Participating in Decisions About Your Care with Your Health Care Team 1:03:12

27d ago1:03:12

1:03:12

- How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects, & Pain Management- What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care- What to Consider When Selecting a Cancer Care Team & Treatme…

1
A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset 20:30

1M ago20:30

20:30

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-c…

1
Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances 59:18

1M ago59:18

59:18

Professor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here.…

1
012 Treatment Without Transplant: What Older Myeloma Patients Need to Know 32:05

1M ago32:05

32:05

Welcome to The Myeloma Minutes. This episode explores the standard treatment for older or transplant-ineligible patients with myeloma, focusing on the DRD regimen, its side effects, and supportive care options. 📌Key points: The DRD combo (Daratumumab, Lenalidomide, Dexamethasone) can keep myeloma controlled for years—even in older patients. Steroid…

1
Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma 9:47

1M ago9:47

9:47

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, invol…

1
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances 59:08

1M ago59:08

59:08

Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. CME information and select publications here.…

1
Current Perspectives on the Future of Cancer Research 1:05:29

1M ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
How I Treat Series on Geriatric Hematology 17:19

1M ago17:19

17:19

In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.By American Society of Hematology

1
Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance 16:06

1M ago16:06

16:06

In this week's episode, we’ll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences …

1
011 Understanding Induction Therapy for Myeloma 34:42

1M ago34:42

34:42

Welcome to The Myeloma Minutes. This episode guides you as a patient or carer through induction therapy for myeloma, focusing on the DVTD regimen, its side effects, supportive treatments, and how to manage them. 💡You'll learn: How four powerful drugs work together to fight myeloma — and why you don’t need to suffer through side effects. That neurop…

1
EM Quick Hits 65 Occipital Nerve Block, PoCUS in Pulmonary Embolism, Myelopathy, Team Resuscitation, Incidental Neutropenia, Peer Programs 1:08:14

1M ago1:08:14

1:08:14

On this month's EM Quick Hits podcast: Dr. Mathew MacArther on Occipital Nerve Block, Dr. Ian Chernoff on PoCUS in Pulmonary Embolism, Dr. Hans Rosenberg on Myelopathy, Dr. Shawn Segeren on Team Resuscitation, Dr. Brit Long on Incidental Neutropenia and Dr. Kylie Booth on Peer Programs. Please help ensure continued Free Open Access of the entire EM…

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

1M ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit 47:55

1M ago47:55

47:55

Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  CME information and select publications here.By Dr. Neil Love

1
Multiple Myeloma — Fourth Annual National General Medical Oncology Summit 50:41

1M ago50:41

50:41

Clinical investigators discuss available data guiding the management of multiple myeloma.  CME information and select publications here.By Dr. Neil Love

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

2M ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE 19:46

2M ago19:46

19:46

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: …

1
Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 50:50

2M ago50:50

50:50

Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here.By Dr. Neil Love

1
010 The First Steps in Myeloma Care: What to Expect and Why It Matters 29:52

2M ago29:52

29:52

Welcome to The Myeloma Minutes. During this episode, Drs Jam and Sally provide a clear and compassionate guide to first-line treatment for multiple myeloma. 💡You'll learn: About 'induction', 'consolidation' and 'maintenance'—and why they matter. Why pathways can often be dictated by age/health. ...And that the aim isn’t just survival—it’s living we…

1
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 48:22

2M ago48:22

48:22

Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here.By Dr. Neil Love

1
Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 18:31

2M ago18:31

18:31

In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School i…

1
Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies 42:34

2M ago42:34

42:34

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME informati…

1
How I Treat Transfusion Medicine (part 2) 33:57

2M ago33:57

33:57

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George. Find the full published review series in Volume 145 Issue 20 of Blood Journal.By American Society of Hematology

1
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19 ... 20:57

2M ago20:57

20:57

In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acut…

1
009 Bone Disease, Bisphosphonates & Myeloma: What You Need to Know 28:07

2M ago28:07

28:07

Welcome to The Myeloma Minutes. This episode explores how bone disease affects people with multiple myeloma and how bisphosphonates like zolendronic acid can help manage pain, prevent fractures, and support treatment. 📌 Three Big Takeaways Bone disease isn’t inevitable in myeloma—but needs fast action when it strikes! Zolendronic acid can protect y…

1
Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies 49:54

2M ago49:54

49:54

Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here.By Dr. Neil Love

1
Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy 37:08

2M ago37:08

37:08

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME informati…

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

2M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
When to STOP Treatment for Immune Thrombocytopenia in Patients Experiencing a Complete Response on Thrombopoietin Receptor Agonists 10:34

2M ago10:34

10:34

In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-t…

1
How I Treat Transfusion Medicine (part 1) 32:12

2M ago32:12

32:12

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RB…

1
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT 18:15

2M ago18:15

18:15

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differe…

1
008 Scans and Myeloma : What you need to know, with Dr Shaheel Bhuva 44:16

2M ago44:16

44:16

Welcome to The Myeloma Minutes. Dr Shaheel Bhuva, a radiologist (and long term colleague of Jam) joins Drs Jam and Sally to demystify scans in myeloma—explaining what they show, when they're used, and he'll dispel some myths around harmful amounts of radiation! 3 Key Teakaways: Not all bone damage shows up on X-rays—some scans reveal disease before…

1
Ep 204 High Risk Pulmonary Embolism Management 1:24:06

2M ago1:24:06

1:24:06

There are many nuances in the management of patients with pulmonary embolism in cardiac arrest, peri-arrest or simply in shock: We need to optimize oxygenation and airway management, hemodynamic support, acid/base management, thrombolysis and/or catheter-directed therapies that Anton dives into with guest experts Dr. Lauren Westafer, Dr. Bourke Til…

1
Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit 50:03

2M ago50:03

50:03

Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  CME information and select publications here.By Dr. Neil Love